Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Ablation Index and VISITAG™ (ABI-173) (VISTAX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03062046
Recruitment Status : Completed
First Posted : February 23, 2017
Last Update Posted : May 29, 2019
Sponsor:
Information provided by (Responsible Party):
Biosense Webster, Inc.

Brief Summary:
The purpose of this study is to assess the safety, acute and long term effectiveness, during standard RF ablation procedures while using Ablation Index and VISITAG™ software in combination with a Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter. Furthermore, the role of Ablation Index and VISITAG™ workflow in creating contiguous ablation lines is assessed. The study is a prospective, non-randomized, post-market clinical evaluation. Up to 330 patients will be included in this study. All patients who qualify based on the study specific requirements will be invited to participate. The total duration of the study is estimated to be about 24 months (12 months enrollment period and 12 months of follow up). The clinical investigation population include subjects undergoing RF ablation for treatment of drug resistant symptomatic paroxysmal AF. Prior to enrollment in the clinical investigation, all subjects must meet the inclusion/exclusion criteria and are suitable candidates for enrollment in a clinical investigation in the opinion of the investigator. Subjects must have failed at least one antiarrhythmic drug (AAD) (Type I or III, including β-blocker) as evidenced by recurrent or are intolerant of the AAD.

Condition or disease Intervention/treatment Phase
Paroxysmal Atrial Fibrillation Device: RF ablation Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 340 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Ablation Index and VISITAG™ Use for Pulmonary Vein Isolation (PVI) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Actual Study Start Date : January 27, 2017
Actual Primary Completion Date : March 27, 2019
Actual Study Completion Date : March 27, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RF ablation
Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
Device: RF ablation
RF ablation




Primary Outcome Measures :
  1. Incidence of primary adverse events [ Time Frame: 7 days ]
    A Primary adverse event (PAE) is a serious adverse event, which occurs within the first week (7 days) following an AF ablation procedure with use of ablation index.

  2. confirmation of entrance block [ Time Frame: intraoperative ]
    Presence/absence of acute reconnection will be evaluated through a 30 minute waiting period and adenosine challenge. PVs where acute reconnection is identified during the waiting period or following adenosine challenge will be considered ablation index false positives

  3. long-term effectiveness [ Time Frame: 12 months ]
    Freedom from documented atrial arrhythmia (atrial fibrillation (AF), atrial tachycardia (AT) or atrial flutter (AFL)) episodes (episodes ≥ 30 sec on arrhythmia monitoring device) during the effectiveness evaluation period (day 91-365)


Secondary Outcome Measures :
  1. Incidence of individual PAE versus total number of PAE [ Time Frame: 12 months ]
    Incidence of individual PAE versus total number of PAE occured during study

  2. Incidence of entrance block after first encirclement (prior to 30-min waiting period) [ Time Frame: intraoperative ]
    % of subjects with ipsilateral PV isolation (entrance block) after first encirclement (evaluated prior to the 30 minute waiting period and adenosine challenge)

  3. Long-term effectiveness: freedom from documented symptomatic atrial arrhythmia [ Time Frame: from 3 up to 12 months ]
    Freedom from documented symptomatic atrial arrhythmia (AF, AT and AFL) episodes (episodes ≥ 30 sec on arrhythmia monitoring device) during the effectiveness evaluation period (day 91-365)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Symptomatic paroxysmal AF who had at least one AF episode electrocardiographically documented within one (1) year prior to enrollment. Documentation may include electrocardiogram (ECG); Transtelephonic monitoring (TTM), holter monitor or telemetry strip
  2. Failed at least one antiarrhythmic drug (AAD) (Type I or III, including β-blocker) as evidenced by recurrent symptomatic AF, or intolerance to the AAD
  3. Age 18 years or older
  4. Signed Patient Informed Consent Form (ICF)
  5. Able and willing to comply with all pre-, post-, and follow-up testing and requirements

Exclusion Criteria:

  1. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  2. Previous LA ablation or surgery
  3. Anticipated to receive ablation outside the PV ostia and CTI region
  4. Previously diagnosed with persistent AF (> 7 days in duration)
  5. LA size >50 mm
  6. LA thrombus
  7. LVEF < 40%
  8. Uncontrolled heart failure or NYHA Class III or IV
  9. History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  10. History of a documented thromboembolic event (including TIA) within the past 6 months
  11. Previous PCI/MI within the past 3 months
  12. Previous cardiac surgery (e.g. CABG) within the past 6 months
  13. Previous valvular cardiac surgical/percutaneous procedure (e.g. ventriculotomy, atriomy, valve repair or replacement, presence of a prosthetic valve)
  14. Unstable angina pectoris
  15. Awaiting cardiac transplantation, cardiac surgery or other major surgery within the next 12 months.
  16. Significant pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
  17. Acute illness, active systemic infection or sepsis
  18. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation.
  19. Presence of a condition that precludes vascular access
  20. Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this trial
  21. Current enrollment in an investigational study evaluating another device or drug.
  22. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)
  23. Life expectancy less than 12 months
  24. Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions For Use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03062046


Locations
Show Show 17 study locations
Sponsors and Collaborators
Biosense Webster, Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Biosense Webster, Inc.
ClinicalTrials.gov Identifier: NCT03062046    
Other Study ID Numbers: ABI-173
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: May 29, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Biosense Webster, Inc.:
Atrial Fibrillation
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes